Osteoporosis has long been explained as a simple mismatch: bone-forming cells fall behind bone-resorbing cells, and the skeleton slowly thins. A new review published in Cellular & Molecular Biology Letters argues that this classical picture is incomplete. Beyond the imbalance between formation and resorption, the authors connect osteoporosis to age-related disruption of skeletal cell metabolism, proposing that the energy programs inside osteoblasts, osteoclasts, osteocytes and bone marrow stromal cells are themselves targets for diagnosis and treatment.
Each of these cell types relies on a distinct combination of glycolysis, oxidative phosphorylation, fatty acid metabolism and glutamine utilization to carry out its work. Osteoblasts must produce and mineralize bone matrix; osteoclasts must fuel the energetically demanding process of resorbing it; osteocytes and stromal cells coordinate remodeling signals from within the bone. The review emphasizes that these metabolic programs are progressively disturbed with aging by mitochondrial dysfunction, oxidative stress, depletion of nicotinamide adenine dinucleotide (NAD+), altered nutrient-sensing pathways, bone marrow adiposity and cellular senescence.
The authors frame the review as a synthesis of potential effects of these changes on bone remodeling rather than a report of new experimental results. As a review article, it reorganizes existing knowledge around a metabolic lens, and its claims about how specific metabolic shifts alter remodeling are presented as potential mechanisms supported by prior literature rather than as directly measured outcomes in a new study.
A central contribution of the review is its careful re-examination of currently approved anti-osteoporotic agents from a metabolic perspective. For bisphosphonates, denosumab, calcitonin, selective estrogen receptor modulators, teriparatide and romosozumab, the authors draw a sharp distinction between the relatively few instances in which metabolic effects have been measured directly in skeletal cells and the larger number of effects inferred from the pathways these agents target. This distinction matters because pathway-based inference can suggest metabolic mechanisms that have not yet been confirmed experimentally in bone cells.
Beyond repurposing existing drugs, the review surveys emerging approaches that more directly target skeletal metabolism. These include NAD+ repletion, inhibition of the NAD+-consuming enzyme CD38, mitochondria-targeted antioxidants, modulation of the adenosine monophosphate-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR) pathways, senolytics and senomorphics that clear or suppress senescent cells, and interventions based on metabolic substrates or nutrition.
The authors are explicit that these strategies remain opportunities rather than proven therapies. They may act upstream of the final bone remodeling imbalance, potentially addressing root causes instead of downstream consequences, but their translation is constrained by metabolic heterogeneity among cell types, systemic off-target effects and narrow therapeutic windows for treatment timing and dose. A molecule that boosts energy metabolism in osteoblasts could, in principle, do the same in unwanted cell populations elsewhere in the body.
To navigate these constraints, the review proposes that future therapeutic strategies may require metabolic subtyping of patients, bone-selective delivery systems and rational combinations with established anabolic or antiresorptive drugs. The goal, as the authors describe it, is to restore skeletal metabolic resilience during aging rather than merely to slow bone loss after it has begun.
The review’s open-access publication on 2 November 2026 makes this metabolic framework available to researchers and clinicians without subscription barriers. Its authors, led by Hao Chen and Lu Zhang, span multiple institutions, and the article carries the permanent DOI 10.1186/s11658-026-01040-5. The publisher notes that the version shared is a peer-reviewed accepted manuscript subject to further edits before the final Version of Record.
For the field, the significance lies in reframing: osteoporosis is presented not only as a remodeling disease but as a metabolic aging disease of the skeleton. Whether NAD+ repletion, senolytics or AMPK modulation can safely improve bone health in humans remains to be tested, but the review provides a structured map of where those tests should look first.
Subject of Research: Age-related metabolic changes in bone cells and their implications for osteoporosis therapy
Article Title: Metabolic aging of the skeleton: mechanisms and therapeutic opportunities in osteoporosis
Article References: Chen, H., Liu, M., Jia, S., Gao, X., Shao, J., Zhao, R., Liang, Q., You, Y., Meng, C., Zhu, Z., & Zhang, L. (2026). Metabolic aging of the skeleton: mechanisms and therapeutic opportunities in osteoporosis. Cellular & Molecular Biology Letters. https://doi.org/10.1186/s11658-026-01040-5
Image Credits: AI Generated
DOI: 10.1186/s11658-026-01040-5
Keywords: osteoporosis, bone metabolism, NAD+, mitochondrial dysfunction, senolytics, osteoblasts, osteoclasts, bone marrow adiposity, teriparatide, romosozumab, AMPK, aging
News Source: Beatrice Stafford. (November 7, 2026). Skeleton’s metabolic aging reshapes osteoporosis research. Scienmag.
